alexa Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis.


Journal of Hepatology and Gastrointestinal disorders

Author(s): MolinaInfante J, Katzka DA, Gisbert JP

Abstract Share this page

Abstract BACKGROUND: Recent advances in eosinophilic oesophagitis (EoE) have confirmed the existence of a new disease phenotype, proton pump inhibitor (PPI)-responsive oesophageal eosinophilia (PPI-REE). AIM: To summarise evidence supporting the use of PPI therapy in patients with suspected EoE (oesophageal dysfunction plus >15 eos/HPF in oesophageal biopsies). METHODS: A literature search was conducted through MEDLINE, using the MeSH search terms 'eosinophilic oesophagitis', 'proton pump inhibitors' and 'oesophageal eosinophilia'. Relevant articles and their reference lists were identified through manual review. RESULTS: Ten articles, including 258 patients with suspected EoE (152 children, 106 adults) undergoing clinico-histological re-evaluation after PPI therapy, were identified. In children, clinical response ranged from 78\% to 86\% and histological remission from 23\% to 40\%. In adults, symptom response ranged from 25\% to 80\% and histological remission from 33\% to 61\%. Among PPI-REE patients with oesophageal pH-monitoring, 35 showed pathological and 10 normal studies. PPI-REE was significantly commoner with documented gastro-oesophageal reflux disease (GERD) when compared to patients with negative pH monitoring (70\% vs. 29\%, P < 0.001). Symptom improvement/resolution occurred in 50-85\% of patients without histological remission on PPI therapy. Six PPI-REE patients demonstrated clinico-histological relapse on PPI therapy. CONCLUSIONS: At least one third of patients with suspected EoE achieve clinico-histological remission on PPI therapy. Response is more limited in children compared with that in adults. pH monitoring does not accurately predict response to PPI therapy, albeit histological remission is significantly higher, up to 70\%, upon documented GERD. Symptom improvement is common with PPI therapy despite persistent eosinophilic infiltration. © 2013 John Wiley & Sons Ltd. This article was published in Aliment Pharmacol Ther and referenced in Journal of Hepatology and Gastrointestinal disorders

Relevant Expert PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version